Opposite Phenotypes of Muscle Strength and Locomotor Function in Mouse Models of Partial Trisomy and Monosomy 21 for the Proximal Hspa13-App Region

PLoS Genetics

Volumn 11, Issue 3, 2015, Pages

  Brault, Véronique ^a,b,c,d   Duchon, Arnaud ^a,b,c,d   Romestaing, Caroline ^e   Sahun, Ignasi ^f   Pothion, Stéphanie ^b   Karout, Mona ^a,b,c,d   Borel, Christelle ^g   Dembele, Doulaye ^a,b,c,d   Bizot, Jean Charles ^h   Messaddeq, Nadia ^a,b,c,d   Sharp, Andrew J ⁱ   Roussel, Damien ^e   Antonarakis, Stylianos E ^g,j   Dierssen, Mara ^f   Hérault, Yann ^a,b,c,d,k  

^a INSTITUT DE GÉNÉTIQUE ET DE BIOLOGIE MOLÉCULAIRE ET CELLULAIRE   (France)

^b CNRS   (France)

^c INSERM   (France)

^d UNIVERSITÉ DE STRASBOURG   (France)

^e UNIVERSITÉ DE LYON   (France)

^f CENTRE FOR GENOMIC REGULATION CRG   (Spain)

^g UNIVERSITY OF GENEVA MEDICAL SCHOOL   (Switzerland)

^h Key Obs SAS   (France)

ⁱ MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^j Institute of Genetics and Genomics of Geneva (iGE3)   (Switzerland)

^k INSTITUT CLINIQUE DE LA SOURIS   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APP GENE; ARTICLE; BIOGENESIS; CELL ACTIVITY; CELL MEMBRANE PERMEABILITY; CELL PROLIFERATION; CHROMOSOME 21; CONTROLLED STUDY; COPY NUMBER VARIATION; DISEASE ACTIVITY; DISEASE ASSOCIATION; DOWN REGULATION; ENERGY BALANCE; GENE; GENE CONTROL; GENE FUNCTION; GENE IDENTIFICATION; GENE LOCATION; HSPA13 GENE; LOCOMOTION; MALE; MITOCHONDRION; MOLECULAR PATHOLOGY; MONOSOMY; MOUSE; MUSCLE MASS; MUSCLE METABOLISM; MUSCLE STRENGTH; NONHUMAN; PARTIAL TRISOMY; PHENOTYPE; PROMOTER REGION; SIGNAL TRANSDUCTION; SKELETAL MUSCLE; UPREGULATION; ANIMAL; DISEASE MODEL; DOWN SYNDROME; ENERGY METABOLISM; GENETICS; HUMAN; METABOLISM; MOTOR ACTIVITY; MUSCLE MITOCHONDRION; PATHOLOGY; PATHOPHYSIOLOGY;

MUS;

ATP5B PROTEIN, MOUSE; GA BINDING PROTEIN; GABPA PROTEIN, MOUSE; NUCLEAR PROTEIN; PROTON TRANSPORTING ADENOSINE TRIPHOSPHATE SYNTHASE; RECEPTOR INTERACTING PROTEIN 140; SIGNAL TRANSDUCING ADAPTOR PROTEIN;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; CHROMOSOMES, HUMAN, PAIR 21; DISEASE MODELS, ANIMAL; DOWN SYNDROME; ENERGY METABOLISM; GA-BINDING PROTEIN TRANSCRIPTION FACTOR; HUMANS; MICE; MITOCHONDRIA, MUSCLE; MITOCHONDRIAL PROTON-TRANSLOCATING ATPASES; MONOSOMY; MOTOR ACTIVITY; MUSCLE STRENGTH; MUSCLE, SKELETAL; NUCLEAR PROTEINS;

EID: 84926306807     PISSN: 15537390     EISSN: 15537404     Source Type: Journal    
DOI: 10.1371/journal.pgen.1005062     Document Type: Article

References (102)

1. Joosten AMS, DeVos S, VanOpstal D, Brandenburg H, Gaillard JLJ, VermeijKeers C, Full monosomy 21, prenatally diagnosed by fluorescent in situ hybridization. Prenatal Diagnosis. 1997;17(3):271–5. doi: 10.1002/(sici)1097-0223(199703)17:3<271::aid-pd51>3.0.co;2-p 9110372
2. Kulharya AS, Tonk VS, Lovell C, Flannery DB, Complete Monosomy 21 Confirmed by FISH and Array-CGH. American Journal of Medical Genetics Part A. 2012;158A(4):935–7. doi: 10.1002/ajmg.a.35251 22407893
3. Manolakos E, Peitsidis P, Eleftheriades M, Dedoulis E, Ziegler M, Orru S, et al. Prenatal detection of full monosomy 21 in a fetus with increased nuchal translucency: Molecular cytogenetic analysis and review of the literature. Journal of Obstetrics and Gynaecology Research. 2010;36(2):435–40. doi: 10.1111/j.1447-0756.2009.01140.x 20492403
4. Mori MA, Lapunzina P, Delicado A, Nunez G, Rodriguez JI, de Torres ML, et al. A prenatally diagnosed patient with full monosomy 21: Ultrasound, cytogenetic, clinical, molecular, and necropsy findings. American Journal of Medical Genetics Part A. 2004;127A(1):69–73. doi: 10.1002/ajmg.a.20622 15103721
5. Fisher D, DiPietro A, Murdison KA, Lemieux CA, Full Monosomy 21: Echocardiographic Findings in the Third Molecularly Confirmed Case. Pediatric Cardiology. 2013;34(3):733–5. doi: 10.1007/s00246-012-0334-4 22562777
6. Wakui K, Toyoda A, Kubota T, Hidaka E, Ishikawa M, Katsuyama T, et al. Familial 14-Mb deletion at 21q11.2-q21.3 and variable phenotypic expression. Journal of Human Genetics. 2002;47(10):511–6. doi: 10.1007/s100380200076 12376739
7. Tinkel-Vernon H, Finkernagel S, Desposito F, Pittore C, Reynolds K, Sciorra L, Patient with a deletion of chromosome 21q and minimal phenotype. American Journal of Medical Genetics Part A. 2003;120A(1):142–3. doi: 10.1002/ajmg.a.10210 12794708
8. Chettouh Z, Croquette MF, Delobel B, Gilgenkrants S, Leonard C, Maunoury C, et al. MOLECULAR MAPPING OF 21 FEATURES ASSOCIATED WITH PARTIAL MONOSOMY-21—INVOLVEMENT OF THE APP-SOD1 REGION. American Journal of Human Genetics. 1995;57(1):62–71. 7611297
9. Lindstrand A, Malmgren H, Sahlen S, Schoumans J, Nordgren A, Ergander U, et al. Detailed molecular and clinical characterization of three patients with 21q deletions. Clinical Genetics. 2010;77(2):145–54. doi: 10.1111/j.1399-0004.2009.01289.x 19863549
10. Roberson EDO, Wohler ES, Hoover-Fong JE, Lisi E, Stevens EL, Thomas GH, et al. Genomic analysis of partial 21q monosomies with variable phenotypes. European Journal of Human Genetics. 2011;19(2):235–8. doi: 10.1038/ejhg.2010.150 20823914
11. Korenberg JR, Kalousek DK, Anneren G, Pulst SM, Hall JG, Epstein CJ, et al. DELETION OF CHROMOSOME-21 AND NORMAL INTELLIGENCE—MOLECULAR DEFINITION OF THE LESION. Human Genetics. 1991;87(2):112–8. doi: 10.1007/bf00204163 2066097
12. Lyle R, Béna F, Gagos S, Gehrig C, Lopez G, Schinzel A, et al. Genotype-phenotype correlations in Down syndrome identified by array CGH in 30 cases of partial trisomy and partial monosomy chromosome 21. Eur J Hum Genet. 2009;17(4):454–66. doi: 10.1038/ejhg.2008.214 19002211
13. Parker SE, Mai CT, Canfield MA, Rickard R, Wang Y, Meyer RE, et al. Updated National Birth Prevalence Estimates for Selected Birth Defects in the United States, 2004–2006. Birth Defects Research Part a-Clinical and Molecular Teratology. 2010;88(12):1008–16. doi: 10.1002/bdra.20735
14. Korbel J, Tirosh-Wagner T, Urban A, Chen X, Kasowski M, Dai L, et al. The genetic architecture of Down syndrome phenotypes revealed by high-resolution analysis of human segmental trisomies. Proc Natl Acad Sci U S A. 2009;106(29):12031–6. doi: 10.1073/pnas.0813248106 19597142
15. Anderson DI, Campos JJ, Witherington DC, Dahl A, Rivera M, He MX, et al. The role of locomotion in psychological development. Frontiers in Psychology. 2013;4. doi: 10.3389/fpsyg.2013.00440
16. Campos JJ, Anderson DI, Barbu-Roth MA, Hubbard EM, Hertenstein MJ, Witherington D, Travel Broadens the Mind. Infancy. 2000;1(2):149–219. doi: 10.1207/s15327078in0102_1
17. Frith U, Frith CD, SPECIFIC MOTOR DISABILITIES IN DOWNS-SYNDROME. Journal of Child Psychology and Psychiatry and Allied Disciplines. 1974;15(4):293–301.
18. Shumwaycook A, Woollacott MH, DYNAMICS OF POSTURAL CONTROL IN THE CHILD WITH DOWN SYNDROME. Physical Therapy. 1985;65(9):1315–22. 3162178
19. Hestnes A, Stovner LJ, Husoy O, Folling I, Fougner KJ, Sjaastad O, HORMONAL AND BIOCHEMICAL DISTURBANCES IN DOWNS-SYNDROME. Journal of Mental Deficiency Research. 1991;35:179–93. 1833549
20. Gonzalez-Aguero A, Ara I, Moreno LA, Vicente-Rodriguez G, Casajus JA, Fat and lean masses in youths with Down syndrome: Gender differences. Research in Developmental Disabilities. 2011;32(5):1685–93. doi: 10.1016/j.ridd.2011.02.023 21435834
21. O'Doherty A, Ruf S, Mulligan C, Hildreth V, Errington ML, Cooke S, et al. An aneuploid mouse strain carrying human chromosome 21 with Down syndrome phenotypes. Science. 2005;309(5743):2033–7. doi: 10.1126/science.1114535 16179473
22. Yu T, Li ZY, Jia ZP, Clapcote SJ, Liu CH, Li SM, et al. A mouse model of Down syndrome trisomic for all human chromosome 21 syntenic regions. Human Molecular Genetics. 2010;19(14):2780–91. doi: 10.1093/hmg/ddq179 20442137
23. Yu T, Liu CH, Belichenko P, Clapcote SJ, Li SM, Pao AN, et al. Effects of individual segmental trisomies of human chromosome 21 syntenic regions on hippocampal long-term potentiation and cognitive behaviors in mice. Brain Research. 2010;1366:162–71. doi: 10.1016/j.brainres.2010.09.107 20932954
24. Li ZY, Yu T, Morishima M, Pao A, LaDuca J, Conroy J, et al. Duplication of the entire 22.9 Mb human chromosome 21 syntenic region on mouse chromosome 16 causes cardiovascular and gastrointestinal abnormalities. Human Molecular Genetics. 2007;16(11):1359–66. doi: 10.1093/hmg/ddm086 17412756
25. Pereira PL, Magnol L, Sahun I, Brault V, Duchon A, Prandini P, et al. A new mouse model for the trisomy of the Abcg1-U2af1 region reveals the complexity of the combinatorial genetic code of down syndrome. Human Molecular Genetics. 2009;18(24):4756–69. doi: 10.1093/hmg/ddp438 19783846
26. Reeves RH, Irving NG, Moran TH, Wohn A, Kitt C, Sisodia SS, et al. A mouse model for Down syndrome exhibits learning and behaviour deficits. Nat Genet. 1995;11(2):177–84. 7550346
27. Duchon A, Raveau M, Chevalier C, Nalesso V, Sharp AJ, Herault Y, Identification of the translocation breakpoints in the Ts65Dn and Ts1Cje mouse lines: relevance for modeling down syndrome. Mamm Genome. 2011. doi: 10.1007/s00335-011-9356-0
28. Duchon A, Raveau M, Chevalier C, Nalesso V, Sharp AJ, Herault Y, Identification of the translocation breakpoints in the Ts65Dn and Ts1Cje mouse lines: relevance for modeling down syndrome. Mammalian Genome. 2011;22(11–12):674–84. doi: 10.1007/s00335-011-9356-0 21761260
29. Costa ACS, Walsh K, Davisson MT, Motor dysfunction in a mouse model for Down syndrome. Physiology & Behavior. 1999;68(1–2):211–20.
30. Costa ACS, Stasko MAP, Schmidt C, Davisson MT, Behavioral validation of the Ts65Dn mouse model for Down syndrome of a genetic background free of the retinal degeneration mutation Pde6b(rd1). Behavioural Brain Research. 2010;206(1):52–62. doi: 10.1016/j.bbr.2009.08.034 19720087
31. Hyde LA, Crnic LS, Pollock A, Bickford PC, Motor learning in Ts65Dn mice, a model for Down syndrome. Developmental Psychobiology. 2001;38(1):33–45. doi: 10.1002/1098-2302(2001)38:1<33::aid-dev3>3.0.co;2-0 11150059
32. Vidal V, Garcia S, Martinez P, Corrales A, Florez J, Rueda N, et al. LACK OF BEHAVIORAL AND COGNITIVE EFFECTS OF CHRONIC ETHOSUXIMIDE AND GABAPENTIN TREATMENT IN THE TS65DN MOUSE MODEL OF DOWN SYNDROME. Neuroscience. 2012;220:158–68. doi: 10.1016/j.neuroscience.2012.06.031 22728103
33. Ault B, Caviedes P, Hidalgo J, Epstein CJ, Rapoport SI, ELECTROPHYSIOLOGICAL ANALYSIS OF CULTURED FETAL MOUSE DORSAL-ROOT GANGLION NEURONS TRANSGENIC FOR HUMAN SUPEROXIDE DISMUTASE-1, A GENE IN THE DOWN SYNDROME REGION OF CHROMOSOME-21. Brain Research. 1989;497(1):191–4. 2529019
34. Nieminen K, Suarezisla BA, Rapoport SI, ELECTRICAL-PROPERTIES OF CULTURED DORSAL-ROOT GANGLION NEURONS FROM NORMAL AND TRISOMY-21 HUMAN-FETAL TISSUE. Brain Research. 1988;474(2):246–54. 2974749
35. Peng S, Rapoport SI, Pearce RJ, Galdzicki Z, Abnormal chloride and potassium conductances in cultured embryonic tongue muscle from trisomy 16 mouse. Developmental Brain Research. 2000;122(2):193–7. 10960688
36. Duchon A, Pothion S, Brault V, Sharp AJ, Tybulewicz VLJ, Fisher EMC, et al. The telomeric part of the human chromosome 21 from Cstb to Prmt2 is not necessary for the locomotor and short-term memory deficits observed in the Tc1 mouse model of Down syndrome. Behavioural Brain Research. 2011;217(2):271–81. doi: 10.1016/j.bbr.2010.10.023 21047530
37. Adams DJ, Biggs PJ, Cox T, Davies R, van der Weyden L, Jonkers J, et al. Mutagenic insertion and chromosome engineering resource (MICER). Nature Genetics. 2004;36(8):867–71. doi: 10.1038/ng1388 15235602
38. Brault V, Besson V, Magnol L, Duchon A, Herault Y, Cre/loxP-mediated chromosome engineering of the mouse genome. Handb Exp Pharmacol. 2007;178:29–48. 17203650
39. Mootha VK, Lepage P, Miller K, Bunkenborg J, Reich M, Hjerrild M, et al. Identification of a gene causing human cytochrome c oxidase deficiency by integrative genomics. Proceedings of the National Academy of Sciences of the United States of America. 2003;100(2):605–10. doi: 10.1073/pnas.242716699 12529507
40. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proceedings of the National Academy of Sciences of the United States of America. 2005;102(43):15545–50. doi: 10.1073/pnas.0506580102 16199517
41. Mootha VK, Lindgren CM, Eriksson KF, Subramanian A, Sihag S, Lehar J, et al. PGC-1 alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nature Genetics. 2003;34(3):267–73. doi: 10.1038/ng1180 12808457
42. Hafner RP, Brown GC, Brand MD, ANALYSIS OF THE CONTROL OF RESPIRATION RATE, PHOSPHORYLATION RATE, PROTON LEAK RATE AND PROTONMOTIVE FORCE IN ISOLATED-MITOCHONDRIA USING THE TOP-DOWN APPROACH OF METABOLIC CONTROL-THEORY. European Journal of Biochemistry. 1990;188(2):313–9. doi: 10.1111/j.1432-1033.1990.tb15405.x 2156698
43. Lambert AJ, Brand MD, Superoxide production by NADH: ubiquinone oxidoreductase (complex I) depends on the pH gradient across the mitochondrial inner membrane. Biochemical Journal. 2004;382:511–7. doi: 10.1042/bj20040485 15175007
44. Pinter JD, Eliez S, Schmitt JE, Capone GT, Reiss AL, Neuroanatomy of Down's syndrome: A high-resolution MRI study. American Journal of Psychiatry. 2001;158(10):1659–65. doi: 10.1176/appi.ajp.158.10.1659 11578999
45. Raz N, Torres IJ, Briggs SD, Spencer WD, Thornton AE, Loken WJ, et al. SELECTIVE NEUROANATOMICAL ABNORMALITIES IN DOWNS-SYNDROME AND THEIR COGNITIVE CORRELATES—EVIDENCE FROM MRI MORPHOMETRY. Neurology. 1995;45(2):356–66. 7854539
46. Weis S, Weber G, Neuhold A, Rett A, DOWN-SYNDROME—MR QUANTIFICATION OF BRAIN STRUCTURES AND COMPARISON WITH NORMAL CONTROL SUBJECTS. American Journal of Neuroradiology. 1991;12(6):1207–11. 1837203
47. Cole KJ, Abbs JH, Turner GS, DEFICITS IN THE PRODUCTION OF GRIP FORCES IN DOWN SYNDROME. Developmental Medicine and Child Neurology. 1988;30(6):752–8. 2976689
48. Ringenbach SD, Chua R, Maraj BKV, Kao JC, Weeks DJ, Bimanual coordination dynamics in adults with Down syndrome. Motor Control. 2002;6(4):388–407. 12429892
49. Aruin AS, Almeida GL, Latash ML, Organization of a simple two-joint synergy in individuals with Down syndrome. American Journal on Mental Retardation. 1996;101(3):256–68. 8933900
50. Latash ML, Learning motor synergies by persons with Down syndrome. Journal of Intellectual Disability Research. 2007;51:962–71. doi: 10.1111/j.1365-2788.2007.01008.x 17991003
51. Cowley PM, Keslacy S, Middleton FA, DeRuisseau LR, Fernhall B, Kanaley JA, et al. Functional and biochemical characterization of soleus muscle in Down syndrome mice: insight into the muscle dysfunction seen in the human condition. American Journal of Physiology-Regulatory Integrative and Comparative Physiology. 2012;303(12):R1251–R60. doi: 10.1152/ajpregu.00312.2012
52. Davis WE, Kelso JAS, ANALYSIS OF INVARIANT CHARACTERISTICS IN THE MOTOR CONTROL OF DOWNS-SYNDROME AND NORMAL SUBJECTS. Journal of Motor Behavior. 1982;14(3):194–212. 15153410
53. Morris AF, Vaughan SE, Vaccaro P, MEASUREMENTS OF NEUROMUSCULAR TONE AND STRENGTH IN DOWNS-SYNDROME CHILDREN. Journal of Mental Deficiency Research. 1982;26(MAR):41–6.
54. Allison DB, Gomez JE, Heshka S, Babbitt RL, Geliebter A, Kreibich K, et al. DECREASED RESTING METABOLIC-RATE AMONG PERSONS WITH DOWN-SYNDROME. International Journal of Obesity. 1995;19(12):858–61. 8963352
55. Luke A, Roizen NJ, Sutton M, Schoeller DA, ENERGY-EXPENDITURE IN CHILDREN WITH DOWN-SYNDROME—CORRECTING METABOLIC-RATE FOR MOVEMENT. Journal of Pediatrics. 1994;125(5):829–38. 7965444
56. Bricout VA, Flore P, Guinot M, Faure P, Garnier P, Eberhard Y, et al. Hormonal responses of Down's syndrome subjects to exercise. Science & Sports. 2007;22(6):293–6. doi: 10.1016/j.scispo.2007.09.002
57. Mercer VS, Lewis CL, Hip Abductor and Knee Extensor Muscle Strength of Children with and without Down Syndrome. Pediatr Phys Ther. 2001;13(1):18–26. 17053646
58. Cenini G, Dowling ALS, Beckett TL, Barone E, Mancuso C, Murphy MP, et al. Association between frontal cortex oxidative damage and beta-amyloid as a function of age in Down syndrome. Biochimica Et Biophysica Acta-Molecular Basis of Disease. 2012;1822(2):130–8. doi: 10.1016/j.bbadis.2011.10.001
59. Busciglio J, Pelsman A, Wong C, Pigino G, Yuan ML, Mori H, et al. Altered metabolism of the amyloid beta precursor protein is associated with mitochondrial dysfunction in Down's syndrome. Neuron. 2002;33(5):677–88. 11879646
60. Iannello RC, Crack PJ, de Haan JB, Kola I, Oxidative stress and neural dysfunction in Down Syndrome. Journal of Neural Transmission-Supplement. 1999;(57):257–67. 10666681
61. Zana M, Janka Z, Kalman J, Oxidative stress: A bridge between Down's syndrome and Alzheimer's disease. Neurobiology of Aging. 2007;28(5):648–76. doi: 10.1016/j.neurobiolaging.2006.03.008 16624449
62. Genova MW, Pich MM, Biondi A, Bernacchia A, Falasca A, Bovina C, et al. Mitochondrial production of oxygen radical species and the role of coenzyme Q as an antioxidant. Experimental Biology and Medicine. 2003;228(5):506–13. 12709577
63. Batandier C, Guigas B, Detaille D, El-Mir MY, Fontaine E, Rigoulet M, et al. The ROS production induced by a reverse-electron flux at respiratory-chain complex 1 is hampered by metformin. Journal of Bioenergetics and Biomembranes. 2006;38(1):33–42. doi: 10.1007/s10863-006-9003-8 16732470
64. Liu YB, Fiskum G, Schubert D, Generation of reactive oxygen species by the mitochondrial electron transport chain. Journal of Neurochemistry. 2002;80(5):780–7. doi: 10.1046/j.0022-3042.2002.00744.x 11948241
65. Hansford RG, Hogue BA, Mildaziene V, Dependence of H2O2 formation by rat heart mitochondria on substrate availability and donor age. Journal of Bioenergetics and Biomembranes. 1997;29(1):89–95. doi: 10.1023/a:1022420007908 9067806
66. Johnson JA, Ogbi M, Targeting the F1Fo ATP Synthase: Modulation of the Body's Powerhouse and Its Implications for Human Disease. Current Medicinal Chemistry. 2011;18(30):4684–714. 21864274
67. Osanai T, Tanaka M, Magota K, Tomita H, Okumura K, Coupling factor 6-induced activation of ecto-F1Fo complex induces insulin resistance, mild glucose intolerance and elevated blood pressure in mice. Diabetologia. 2012;55(2):520–9. doi: 10.1007/s00125-011-2341-z 22038518
68. Valenti D, Tullo A, Caratozzolo MF, Merafina RS, Scartezzini P, Marra E, et al. Impairment of F1F0-ATPase, adenine nucleotide translocator and adenylate kinase causes mitochondrial energy deficit in human skin fibroblasts with chromosome 21 trisomy. Biochemical Journal. 2010;431:299–310. doi: 10.1042/bj20100581 20698827
69. Conti A, Fabbrini F, D'Agostino P, Negri R, Greco D, Genesio R, et al. Altered expression of mitochondrial and extracellular matrix genes in the heart of human fetuses with chromosome 21 trisomy. Bmc Genomics. 2007;8. doi: 268 10.1186/1471-2164-8-268
70. Lee SH, Lee S, Jun HS, Jeong HJ, Cha WT, Cho YS, et al. Expression of the mitochondrial ATPase6 gene and Tfam in Down syndrome. Molecules and Cells. 2003;15(2):181–5. 12803480
71. Hock MB, Kralli A, Transcriptional Control of Mitochondrial Biogenesis and Function. Annual Review of Physiology. 2009;71:177–203. doi: 10.1146/annurev.physiol.010908.163119 19575678
72. Puigserver P, Spiegelman BM, Peroxisome proliferator-activated receptor-gamma coactivator 1 alpha (PGC-1 alpha): Transcriptional coactivator and metabolic regulator. Endocrine Reviews. 2003;24(1):78–90. doi: 10.1210/er.2002-0012 12588810
73. Scarpulla RC, Nuclear activators and coactivators in mammalian mitochondrial biogenesis. Biochimica Et Biophysica Acta-Gene Structure and Expression. 2002;1576(1–2):1–14. doi: 10.1016/s0167-4781(02)00343-3
74. Scarpulla RC, Transcriptional activators and coactivators in the nuclear control of mitochondrial function in mammalian cells. Gene. 2002;286(1):81–9. doi: 10.1016/s0378-1119(01)00809-5 11943463
75. Dominy JE, Puigserver P, Mitochondrial Biogenesis through Activation of Nuclear Signaling Proteins. Cold Spring Harbor Perspectives in Biology. 2013;5(7). doi: 10.1101/cshperspect.a015008
76. Mootha VK, Handschin C, Arlow D, Xie XH, St Pierre J, Sihag S, et al. Err alpha and Gabpa/b specify PGC-1 alpha-dependent oxidative phosphorylation gene expression that is altered in diabetic muscle (vol 101, pg 6570, 2004). Proceedings of the National Academy of Sciences of the United States of America. 2005;102(29):10405-. doi: 10.1073/pnas.0505194102
77. Villena JA, Vinas O, Mampel T, Iglesias R, Giralt M, Villarroya F, Regulation of mitochondrial biogenesis in brown adipose tissue: nuclear respiratory factor-2/GA-binding protein is responsible for the transcriptional regulation of the gene for the mitochondrial ATP synthase beta subunit. Biochemical Journal. 1998;331:121–7. 9512469
78. Yang ZF, Mott S, Rosmarin AG, The Ets transcription factor GABP is required for cell-cycle progression. Nature Cell Biology. 2007;9(3):339–U164. doi: 10.1038/ncb1548 17277770
79. Ristevski S, O'Leary DA, Thornell AP, Owen MJ, Kola I, Hertzog PJ, The ETS transcription factor GABP alpha is essential for early embryogenesis. Molecular and Cellular Biology. 2004;24(13):5844–9. doi: 10.1128/mcb.24.13.5844-5849.2004 15199140
80. Yang ZF, Drumea K, Mott S, Wang JL, Rosmarin AG, GABP Transcription Factor (Nuclear Respiratory Factor 2) Is Required for Mitochondrial Biogenesis. Molecular and Cellular Biology. 2014;34(17):3194–201. doi: 10.1128/mcb.00492-12 24958105
81. O'Leary DA, Pritchard MA, Xu DK, Kola I, Hertzog PJ, Ristevski S, Tissue-specific overexpression of the HSA21 gene GABP alpha: implications for DS. Biochimica Et Biophysica Acta-Molecular Basis of Disease. 2004;1739(1):81–7. doi: 10.1016/j.bbadis.2004.09.005
82. Cavailles V, Fine tuning of transcription by nuclear hormone receptors cofactors. M S-Medecine Sciences. 1998;14(10):1127–8.
83. Lee CH, Chinpaisal C, Wei LN, Cloning and characterization of mouse RIP140, a corepressor for nuclear orphan receptor TR2. Molecular and Cellular Biology. 1998;18(11):6745–55. 9774688
84. Cavailles V, Dauvois S, Danielian PS, Parker MG, INTERACTION OF PROTEINS WITH TRANSCRIPTIONALLY ACTIVE ESTROGEN-RECEPTORS. Proceedings of the National Academy of Sciences of the United States of America. 1994;91(21):10009–13. doi: 10.1073/pnas.91.21.10009 7937828
85. White R, Morganstein D, Christian M, Seth A, Herzog B, Parker MG, Role of RIP140 in metabolic tissues: Connections to disease. Febs Letters. 2008;582(1):39–45. doi: 10.1016/j.febslet.2007.11.017 18023280
86. Seth A, Steel JH, Nichol D, Pocock V, Kumaran MK, Fritah A, et al. The transcriptional corepressor RIP140 regulates oxidative metabolism in skeletal muscle. Cell Metabolism. 2007;6(3):236–45. doi: 10.1016/j.cmet.2007.08.004 17767910
87. Izzo A, Manco R, Bonfiglio F, Cali G, de Cristofaro T, Patergnani S, et al. NRIP1/RIP140 siRNA-mediated Attenuation Counteracts Mitochondrial Dysfunction In Down Syndrome. Human Molecular Genetics. 2014;23(16):43. doi: 10.1093/hmg/ddu157
88. Galmiche L, Serre V, Beinat M, Assouline Z, Lebre AS, Chretien D, et al. Exome Sequencing Identifies MRPL3 Mutation in Mitochondrial Cardiomyopathy. Human Mutation. 2011;32(11):1225–31. doi: 10.1002/humu.21562 21786366
89. Miller C, Saada A, Shaul N, Shabtai N, Ben-Shalom E, Shaag A, et al. Defective mitochondrial translation caused by a ribosomal protein (MRPS16) mutation. Annals of Neurology. 2004;56(5):734–8. doi: 10.1002/ana.20282 15505824
90. Saada A, Shaag A, Amon S, Dolfin T, Miller C, Fuchs-Telem D, et al. Antenatal mitochondrial disease caused by mitochondrial ribosomal protein (MRPS22) mutation. Journal of Medical Genetics. 2007;44(12):784–6. doi: 10.1136/jmg.2007.053116 17873122
91. Serre V, Rozanska A, Beinat M, Chretien D, Boddaert N, Munnich A, et al. Mutations in mitochondrial ribosomal protein MRPL12 leads to growth retardation, neurological deterioration and mitochondrial translation deficiency. Biochimica Et Biophysica Acta-Molecular Basis of Disease. 2013;1832(8):1304–12. doi: 10.1016/j.bbadis.2013.04.014 23603806
92. O'Brien TW, O'Brien BJ, Norman RA, Nuclear MRP genes and mitochondrial disease. Gene. 2005;354:147–51. doi: 10.1016/j.gene.2005.03.026 15908146
93. Rotig A, Human diseases with impaired mitochondrial protein synthesis. Biochimica Et Biophysica Acta-Bioenergetics. 2011;1807(9):1198–205. doi: 10.1016/j.bbabio.2011.06.010 21708121
94. Kim JS, He LH, Lemasters JJ, Mitochondrial permeability transition: a common pathway to necrosis and apoptosis. Biochemical and Biophysical Research Communications. 2003;304(3):463–70. doi: 10.1016/s0006-291x(03)00618-1 12729580
95. Zheng BH, Mills AA, Bradley A, A system for rapid generation of coat color-tagged knockouts and defined chromosomal rearrangements in mice. Nucleic Acids Research. 1999;27(11):2354–60. 10325425
96. Magin T, McWhir J, Melton D, A new mouse embryonic stem cell line with good germ line contribution and gene targeting frequency. Nucleic Acids Res. 1992;20(14):3795–6. 1641353
97. Bolstad BM, Irizarry RA, Astrand M, Speed TP, A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics. 2003;19(2):185–93. 12538238
98. Westfall PH, Young SS, P-VALUE ADJUSTMENTS FOR MULTIPLE TESTS IN MULTIVARIATE BINOMIAL MODELS. Journal of the American Statistical Association. 1989;84(407):780–6. doi: 10.2307/2289666 12155379
99. de Hoon MJL, Imoto S, Nolan J, Miyano S, Open source clustering software. Bioinformatics. 2004;20(9):1453–4. doi: 10.1093/bioinformatics/bth078 14871861
100. Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A, et al. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biology. 2002;3(7). doi: 0034.1 10.1186/gb-2002-3-7-research0034 12184816
101. MD B, BGaC CE, Measurement of mitochondrial proton motive force. In: Bioenergetics—A practical approach. Oxford, UK: IRL; 1995. p. 39–62.
102. Rolfe DFS, Hulbert AJ, Brand MD, CHARACTERISTICS OF MITOCHONDRIAL PROTON LEAK AND CONTROL OF OXIDATIVE-PHOSPHORYLATION IN THE MAJOR OXYGEN-CONSUMING TISSUES OF THE RAT. Biochimica Et Biophysica Acta-Bioenergetics. 1994;1188(3):405–16. doi: 10.1016/0005-2728(94)90062-0